CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 7,050 enrolled
Drug / intervention
Alvimopandrug
Likely dose
Alvimopan 12 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01150760
NCT01150760N/ACompleted
CompareCT.gov

Comparison of Clinical Outcomes in Bowel Resection Patients Receiving Alvimopan vs. Patients Not Receiving Alvimopan in the Premier Perspective/Care Science Database

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)·observational·Posted Jun 25, 2010·Updated Aug 7, 2015

In Brief

An observational study evaluating Alvimopan for Ileus. Completed, enrolled 7,050 participants across 1 site.

Detailed Summary

Alvimopan is the first and currently the only FDA-approved therapy for acceleration of the time to upper and lower gastrointestinal (GI) recovery following partial large or small bowel resection surgery with primary anastomosis. The primary objective of this retrospective observational trial is to assess postoperative morbidity and mortality as reported during the index hospitalization for bowel resection and 15/30-day readmissions of alvimopan vs. non-alvimopan matched patients in the combined Premier/Care Science database(a large medical claims database).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsIleus
CountriesUnited States
CollaboratorsGlaxoSmithKline

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 25, 2010
Enrollment StartApr 1, 2010
Primary CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 16.0 years ago

Interventions

Alvimopandrug

At least 1 dose of alvimopan 12 mg during the hospitalization for bowel resection